Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Drug pricing

CMA closes investigation into alleged anticompetitive generic drug pricing practices

Owing to a lack of sufficient evidence of lawbreaking, The Competition and Markets Authority has decided to close its investigation into anticompetitive generic drug pricing.

The Competition and Markets Authority (CMA) has closed an investigation into alleged anticompetitive generic drug pricing after concluding that the case was not a good use of its resources.

The CMA said the investigation had been looking into “suspected breaches of competition law” relating to a range of drugs.

However, the investigation was closed on 14 November 2018 because the body concluded that continuing with the case “would not be the best use of the CMA’s resources”.

The investigation had focused on potential breaches of the Competition Act 1998, but no details were released onwhich companies or organisations were under investigation.

The investigation was launched on 13 October 2017 at the height of the crisis in the generics market that hit community pharmacy. When it launched, the CMA said in a statement that the investigation related “to alleged anticompetitive agreements and/or concerted practices in relation to generic pharmaceutical products”.

The CMA added that it “had not reached a view on whether there is sufficient evidence of an infringement of competition law for it to issue a statement of objections to the parties under investigation”.

In a summary of its decision to close the investigation on 7 November 2018, the CMA said that although this case was now closed, two of the alleged anticompetitive agreements “in relation to generic pharmaceutical products” were being investigated further as two new cases.

The Pharmaceutical Journal previously revealed in July 2018 that the CMA had opened six new investigations into anticompetitive practices in the pharmaceutical sector at the height of the pricing crisis in the generics market. At the time, it was not clear whether the products involved were generics.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20205778

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.